Calidi Biotherapeutics Inc - Ordinary Shares - Class A
CLDI
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.36M
Close$
$0.71
326.1% upside
Current Fair Value
326.1% upsideUndervalued by 326.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.36 Million |
|---|---|
| Enterprise Value | $-3,611,106.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.95 |
| Beta | 1.38 |
| Outstanding Shares | 10,308,000 |
Return
| Return on Equity | -506.79% |
|---|---|
| Return on Assets | -260.77% |
| Return on Invested Capital | -350.98% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | 0.88 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.18 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.46 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 46.70%▲ 37.56% |
|---|---|
| Total Invested | $479,037▼ 8.70% |
| Investors Holding | 29▲ 2.00% |
ESG Score
No data